
-
2000
Company Description
Action Pharma develops pharmaceutical products and treatment concepts for cardiovascular, inflammatory and acquired metabolic diseases.
Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modified ÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
-
Manufacturer:
Science and Engineering -
Formed:
2000 -
Company Website:
-
Company E-mail:
-
Company Address:
Brendstrupgaardsvej 102AarhusDenmark -
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits